TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9114186
Drug: Oral azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral azithromycin (20 mg/kg) administered as a single dose, one dose a week for 3 weeks, or one dose every 4 weeks for a total of six doses
Study: 9114186
Drug: Topical oxytetracycline/polymyxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical oxytetracycline/polymyxin eye ointment (once daily for 5 days every 4 weeks; total of six treatment cycles)
Study: 2667325
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate pretreatment at 0 h before 5-FU
Study: 2667325
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate pretreatment at 3 h before 5-FU
Study: 2667325
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate followed by 5-FU (both doses: 1,000 mg/m2)
Study: 8814
Drug: Chlorpromazine (CPZ)
Normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorpromazine (CPZ) treatment after placebo
Study: 8814
Drug: Acute CPZ
Normalized name: CPZ
DrugBank: Chlorpromazine (DB00477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute CPZ treatment
Study: 27657350
Drug: Magnetic field
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnetic field therapy (MFT)
Study: 21975668
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) 0.14 mg/kg/d for 4 months
Study: 21975668
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CTR) after GH treatment
Study: 21975668
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) after discontinuation
Study: 11301406
Drug: Oral ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ciprofloxacin 20 mg/kg/day p.o. every 12 hours for 6 days
Study: 11301406
Drug: Intravenous ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ceftriaxone plus amikacin for 2 days more followed by cefixime 8 mg/kg/day p.o. every 24 hours for 4 additional days
Study: 8275912
Drug: Paroxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20 mg o.d.)
Study: 8275912
Drug: Clomipramine (increasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine (increasing from 20 mg o.d. to 20 mg tds)
Study: 30563538
Drug: βA (2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: βA (2.4 g·d-1, βA1)
Study: 30563538
Drug: Matched total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched total βA (4.8 g on alternate days, βA2)
Study: 30563538
Drug: Cornflour placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cornflour placebo (2.4 g·d-1, PL)
Study: 28247635
Drug: Basic therapy
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic therapy combined with 10 treatment sessions of hypercapnic hypoxia using a respiratory device
Study: 12435256
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) - 0.625 mg/d of conjugated equine estrogen (plus 2.5 mg/d of medroxyprogesterone acetate for women who had not had a hysterectomy)
Study: 12435256
Drug: Antioxidant vitamins
Normalized name: antioxidant vitamins with minerals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant vitamins - 400 IU of vitamin E twice daily plus 500 mg of vitamin C twice daily
Study: 30945297
Drug: Pomegranate seed
Normalized name: pomegranate seed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate seed oil (PSO) - 1 g daily for 8 weeks
Study: 21544980
Drug: Filgrastim (G-CSF)
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Filgrastim (G-CSF) administration
Study: 17446439
Drug: N(G)-monomethyl-L-arginine (nitric
Approvals — FDA: no, EMA: no, PMDA: no
Description: N(G)-monomethyl-L-arginine (nitric oxide synthase inhibitor)
Study: 15121945
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (5 mg of zinc sulfate daily)
Study: 12516191
Drug: Benzylpenicillin (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzylpenicillin (1.0 g four times daily, i/v) combined with ciprofloxacin (0.5 g twice daily, per os)
Study: 12516191
Drug: Ciprofloxacin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (0.5 g twice daily, per os)
Study: 9695301
Drug: Benzathine penicillin
Normalized name: Benzathine penicillin G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzathine penicillin G (BPG) prophylaxis every 3 weeks as a single intramuscular injection of 1.2 million units for children over 27 kg, and a half dose for those 27 kg or less.
Study: 7857351
Drug: Pidotimod 800
Normalized name: pidotimod
DrugBank: Pidotimod (DB11364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pidotimod 800 mg/die for 60 days
Study: 2751741
Drug: Antacid (Trigastril)
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antacid (Trigastril) with 50 mg pirenzepine
Study: 2751741
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel with 50 mg pirenzepine
Study: 797592
Drug: Betamethasone dipropionate
Normalized name: Betamethasone Dipropionate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone dipropionate cream (Diprosone)
Study: 797592
Drug: Locacorten 0.02%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locacorten 0.02% cream
Study: 31478335
Drug: Gemigliptin 50
Normalized name: gemigliptin
DrugBank: Gemigliptin (DB12412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemigliptin 50 mg once daily
Study: 25178520
Drug: Long-term group
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term group psychotherapy (LTG) - 80 weekly sessions of 90 min each
Study: 25178520
Drug: Short-term group
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term group psychotherapy (STG) - 20 weekly sessions of 90 min each
Study: 21453230
Drug: Steroid-free regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-free regimen (tacrolimus, mycophenolate mofetil, steroids for only 3 days)
Study: 21453230
Drug: Steroid-maintenance regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-maintenance regimen (tacrolimus, mycophenolate mofetil, steroids on a maintenance basis)
Study: 18079005
Drug: Peritonsillar injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peritonsillar injection of tramadol (2 mg/kg)
Study: 18079005
Drug: Intramuscular analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular analgesia with tramadol (2 mg/kg)
Study: 12829675
Drug: Temozolomide 200
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide 200 mg/m2 every 8 hours for five doses
Study: 12829675
Drug: Temozolomide 200
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide 200 mg/m2 daily for days 1 to 5 plus interferon alfa‐2b 5 MU subcutaneously three times a week
Study: 12829675
Drug: Temozolomide 150
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide 150 mg/m2 (increased after one cycle to 200 mg/m2) daily on days 1 to 5 plus thalidomide 100 mg daily days 1 to 28
Study: 1466441
Drug: Hudson mask
Normalized name: MASK,TRACHEOSTOMY HUDSON #1075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hudson mask (48 l.min‐1)
Study: 1466441
Drug: Magill system
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magill system (100 ml.kg‐1.min‐1)
Study: 6689974
Drug: low-dose heparin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: low-dose heparin combined with dihydroergotamine (HDHE)
Study: 14636900
Drug: Low-dose dobutamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dobutamine echocardiography (up to 10 microg/kg/min)
Study: 9056614
Drug: Perindopril (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (4 mg for 15 days)
Study: 8365524
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone (25 mg b.i.d.) during cycle days 16-24 for 10 months
Study: 8365524
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone (25 mg b.i.d.)
Study: 3805300
Drug: Stress inoculation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stress inoculation therapy
Study: 3805300
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of stress inoculation and medication therapy
Study: 26578361
Drug: Continuous ultrasound
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous ultrasound therapy (0.4 W/cm(2 SATA))
Study: 26578361
Drug: Pulsed ultrasound
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed ultrasound therapy (20% duty cycle, 0.08 W/cm(2 SATA))
Study: 26578361
Drug: Continuous ultrasound
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous ultrasound therapy (0.4 W/cm(2 SATA)) after COX inhibition (aspirin)
Study: 26578361
Drug: Pulsed ultrasound
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed ultrasound therapy (20% duty cycle, 0.08 W/cm(2 SATA)) after COX inhibition (aspirin)
Study: 20590434
Drug: 6-session psychoeducative
Normalized name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 100 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 60 mg in 1 mL TOPICAL LOTION [SESSION SAVERS SUNSCREEN BROAD SPECTRUM SPF 30 WATER RESISTANT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-session psychoeducative group therapy module
Study: 19013336
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B (L‐AmB) 3 mg/kg/day
Study: 19013336
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B (L‐AmB) 10 mg/kg/day
Study: 15804471
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg of aspirin once a day for 14 days
Study: 15804471
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of aspirin once a day for 14 days
Study: 15804471
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet for 14 days
Study: 15804471
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (75 mg, 300 mg, and placebo)
Study: 15804471
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg and 300 mg of aspirin
Study: 1518264
Drug: Continuous epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous epinephrine infusion (0.01-0.02 mg/kg) started one hour before and finished one hour after the infusion of E. coli L-asparaginase
Study: 30296472
Drug: Eating As
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eating As Treatment (EAT) intervention delivered by oncology dietitians
Study: 30296472
Drug: Eating As
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eating As Treatment (EAT) intervention
Study: 30307410
Drug: Tacrolimus plus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus plus a single, intraoperative, high-dose (9 mg/kg) rabbit anti-T-lymphocyte globulins (ATLG)
Study: 30307410
Drug: Tacrolimus monotherapy
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus monotherapy (TAC)
Study: 26977624
Drug: Remaxol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remaxol (400 ml intravenously, 2 times a day for 7 days)
Study: 26977624
Drug: Saline with
Normalized name: CVS Saline with Aloe Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline with 25%-magnesium sulfate (10 ml) and 4% potassium chloride (10 ml)
Study: 20825615
Drug: 20 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL/kg perfluorocarbon
Study: 20825615
Drug: 30 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL/kg perfluorocarbon
Study: 20825615
Drug: 40 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mL/kg perfluorocarbon
Study: 17879531
Drug: Migu Tablet
Normalized name: Pseudomonas aeruginosa (schroeter, 1872) migula, 1900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Migu Tablet group (MGTG)
Study: 12376205
Drug: Weekly cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly cisplatin 70 mg/m² (days 1, 8, 15, 29, 36, 43) in combination with escalating doses of paclitaxel (225 mg/m² 4-weekly or 100 mg/m² weekly)
Study: 10102059
Drug: 0.1 IU/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 IU/kg/day (0.03 mg/kg/day), administered once daily (Group A)
Study: 10102059
Drug: 0.2 IU/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 IU/kg/day (0.07 mg/kg/day), administered once daily (Group B)
Study: 10102059
Drug: 0.2 IU/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 IU/kg/day (0.07 mg/kg/day), divided into two equal injections given at 12‐hour intervals (Group C)
Study: 2221415
Drug: 10% Intralipid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% Intralipid (3 mL/min for 20 min)
Study: 2221415
Drug: 5% dextrose
Normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% dextrose in lactated Ringer's solution
Study: 348222
Drug: Fentanyl 0.1
Normalized name: fentanyl 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 0.1 mg and Morphine 10 mg with Droperidol 2.5 mg
Study: 348222
Drug: Fentanyl 0.1
Normalized name: fentanyl 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 0.1 mg and Morphine 10 mg with Droperidol 5.0 mg
Study: 348222
Drug: Fentanyl 0.1
Normalized name: fentanyl 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 0.1 mg and Morphine 10 mg (without Droperidol)
Study: 26016870
Drug: MFGM diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MFGM diet (whipping cream, 40 g milk fat/d)
Study: 26016870
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet (butter oil, 40 g milk fat/d)
Study: 20594878
Drug: Lidocaine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (3 mg/kg/h) and Ketamine (0.6 mg/kg/h) with Morphine (0.24 mg/kg/h)
Study: 20594878
Drug: Lidocaine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (3 mg/kg/h) and Ketamine (0.6 mg/kg/h) with Fentanyl (0.0036 mg/kg/h)
Study: 20594878
Drug: Ringer's lactate
Normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's lactate solution (Control)
Study: 19621198
Drug: Ornithine alpha-ketoglutarate
Normalized name: ornithine alpha-ketoglutarate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ornithine alpha-ketoglutarate (OKG) 10g daily
Study: 17293085
Drug: Mecamylamine (MEC)
DrugBank: Mecamylamine (DB00657)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mecamylamine (MEC) 0.0 mg/day
Study: 17293085
Drug: Mecamylamine (MEC)
DrugBank: Mecamylamine (DB00657)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mecamylamine (MEC) 5.0 mg/day
Study: 17293085
Drug: Mecamylamine (MEC)
DrugBank: Mecamylamine (DB00657)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mecamylamine (MEC) 10.0 mg/day
Study: 10364862
Drug: Conventional Insyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Insyte intravenous cannula (group C)
Study: 8759372
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein isolate beverage powder (60 g/d for 28 d)
Study: 8759372
Drug: Casein supplement
Normalized name: caseins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casein supplement
Study: 2007444
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of Prostaglandin E2 (PGE2) administered by intravaginal route in a hydroxyethyl cellulose gel medium
Study: 31048444
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate solution (4.2 g in 50 mL of 50 mmol/L) with standard preoperative infusion of normal saline (1.5 L)
Study: 31048444
Drug: Placebo (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (50 mL) with standard preoperative infusion of normal saline (1.5 L)
Study: 12118865
Drug: Concurrent auditory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent auditory task
Study: 7818116
Drug: Intravenous oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous oxycodone (7.9 +/- 1.5 mg)
Study: 7818116
Drug: Rectal oxycodone
Normalized name: oxycodone Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal oxycodone (30 mg)
Study: 23110515
Drug: Insecticide treated
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insecticide treated materials (ITMs) including PermaNet 2.0 netting treated with deltamethrin at 55 mg/m2 and targeted interventions (larviciding with Temephos, elimination of breeding sites)
Study: 20507292
Drug: Rituximab therapy
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab therapy (2.0 grams divided into two doses of 1.0 gram on days 1 and 15)
Study: 20507292
Drug: Methotrexate (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (not specified dosage or duration)
Study: 17143011
Drug: Reference preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference preparation containing fusidic acid
Study: 16320790
Drug: Progestin‐only injectable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progestin‐only injectable hormonal contraceptive Norethisterone oenanthate 200 mg
Study: 11142535
Drug: Virtual Reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual Reality Exposure (VRE) therapy
Study: 11142535
Drug: Standard Exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Exposure (SE) therapy
Study: 358754
Drug: Clomipramine (50-125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine (50-125 mg/day)
Study: 358754
Drug: Amitriptyline (50-125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (50-125 mg/day)
Study: 30779375
Drug: fesoterodine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: fesoterodine (4 mg/day)
Study: 30779375
Drug: mirabegron (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: mirabegron (50 mg/day)
Study: 23982939
Drug: CSE‐EVR (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSE‐EVR (combined spinal-epidural anaesthesia) with 0.5 mg per 10 cm height of hyperbaric levobupivacaine and 20 microg fentanyl, followed by 20 mL saline solution injection
Study: 21049267
Drug: THC (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC (400 μg/kg)
Study: 21049267
Drug: Alcohol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.5 mg/ml and 0.7 mg/ml)
Study: 21049267
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 mg/ml)
Study: 16256874
Drug: ICD therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD therapy for ventricular tachycardia (VT) or ventricular fibrillation (VF)
Study: 10515402
Drug: Inhaled terbutaline
Normalized name: terbutaline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled terbutaline (1 mg q.i.d.)
Study: 10515402
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol (100, 100, 200 microg at 5 min intervals)
Study: 8787255
Drug: Caudal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal epidural steroid
Study: 8787255
Drug: Lumbar epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbar epidural steroid
Study: 1799922
Drug: Quinapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril (10 to 20 mg daily)
Study: 1799922
Drug: Enalapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10 to 20 mg daily)
Study: 23473338
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa (to achieve a hemoglobin target of 13 g per deciliter)
Study: 21917440
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate 500 μg (FP500) twice-daily
Study: 15198477
Drug: Probucol (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol (500 mg/day, n=9)
Study: 11028729
Drug: Ropivacaine 3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 3.75 mg/ml
Study: 11028729
Drug: Saline 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 0.3 ml/kg
Study: 3604970
Drug: Fructo-oligosaccharide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructo-oligosaccharide (5 g tid for 12 d)
Study: 3604970
Drug: Sucrose (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose (5 g tid for 12 d)
Study: 3604970
Drug: Fructo-oligosaccharide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructo-oligosaccharide (10 g)
Study: 25201934
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy‐oriented anger management and stress control program (5 sessions, 90 minutes each)